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JunB Deficiency Leads to a Myeloproliferative
Disorder Arising from Hematopoietic Stem Cells
duce mature macrophages and granulocytes (Akashi et
al., 1999).
Within this developmental scheme, leukemias can
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now be viewed as aberrant hematopoietic processesand Medicine
initiated by rare leukemic stem cells (LSC) that undergoDepartments of Pathology and Developmental
an aberrant and poorly regulated process of organogen-Biology
esis analogous to that of normal HSC (Reya et al., 2001;Stanford University School of Medicine
Passegue´ et al., 2003). Since a hallmark of all cancersStanford, California 94305
is the capacity for unlimited self-renewal, it has been2 Research Institute of Molecular Pathology (IMP)
proposed, although never directly demonstrated, thatDr. Bohr-Gasse 7
leukemias may be initiated by transforming events thatA-1030 Vienna
directly take place in the self-renewing LT-HSC. Alterna-Austria
tively, leukemias may also arise from more committed
progenitors that have re-acquired the capacity for indefi-
nite self-renewing proliferation through accumulated
Summary mutations and/or epigenetic changes, as we have re-
cently shown for some human acute myeloid leukemia
The AP-1 transcription factor JunB is a transcriptional (AML) (Miyamoto et al., 2000) and late-stage human
regulator of myelopoiesis. Inactivation of JunB in post- chronic myelogenous leukemia (CML) (Jamieson et al.,
natal mice results in a myeloproliferative disorder 2004). Identifying the developmental origin of the LSC
(MPD) resembling early human chronic myelogenous for each type of leukemia is therefore critical for under-
leukemia (CML). Here, we show that JunB regulates standing their respective biology and providing powerful
the numbers of hematopoietic stem cells (HSC). JunB diagnostic, prognostic, and therapeutic tools in the
overexpression decreases the frequency of long-term clinic.
HSC (LT-HSC), while JunB inactivation specifically ex- At the molecular level, the mechanisms controlling
pands the numbers of LT-HSC and granulocyte/mac- HSC self-renewal activity are still poorly understood.
rophage progenitors (GMP) resulting in chronic MPD. However, the signaling pathways that have been shown
Further, we demonstrate that junB inactivation must to date to be involved in the regulation of HSC self-
take place in LT-HSC, and not at later stages of myelo- renewal, i.e., homeobox genes, such as HoxB4 (Anton-
poiesis, to induce MPD and that only junB-deficient chuk et al., 2002) and HoxA9 (Thorsteinsdottir et al.,
LT-HSC are capable of transplanting the MPD to recip- 2002), Notch (Varnum-Finney et al., 2000), Sonic hedge-
ient mice. These results demonstrate a stem cell-spe- hog (Shh) (Bhardwaj et al., 2001), the Wnt signaling path-
cific role for JunB in normal and leukemic hematopoie- way (Reya et al., 2003), and Bmi-1 (Park et al., 2003;
sis and provide experimental evidence that leukemic Lessard and Sauvageau, 2003), have also been associ-
stem cells (LSC) can reside at the LT-HSC stage of ated with oncogenesis and/or overt leukemia (Reya et
development in a mouse model of MPD. al., 2001; Lessard and Sauvageau, 2003), suggesting the
intriguing hypothesis that similar molecular mechanisms
may control self-renewal activity in normal hematopoi-Introduction
etic stem cells and malignant stem cells.
The AP-1 transcription factor JunB is a transcriptionalHematopoiesis takes place through the stepwise differ-
regulator of myelopoiesis and a potential tumor sup-entiation of multipotent hematopoietic stem cells (HSC)
pressor gene in mice (Passegue´ et al., 2001). Inactivation(Spangrude et al., 1988) to generate a hierarchy of pro-
of junB in knockout mice results in severe vascular de-genitor populations with progressively restricted devel-
fects in the placenta leading to early embryonic lethality,opmental potential, ultimately leading to the production
while constitutive overexpression of junB from the hu-of multiple lineages of mature cells (Orkin, 2000). HSC
man ubiquitin-C promoter (Ubi) has no major conse-can be divided into a long-term subset (LT-HSC), capa-
quences in Ubi-junB transgenic mice (Schorpp-Kistnerble of extensive self-renewal, and a short-term subset
et al., 1999). Reintroducing junB expression in the junB-
(ST-HSC), which self-renews for a limited interval and
deficient background by intercrossing with Ubi-junB
then gives rise to non-self-renewing multipotent progen-
transgenic mice fully rescues the mice from embryonic
itors (MPP) (Morrison et al., 1997; Christensen and lethality (Schorpp-Kistner et al., 1999). However, all re-
Weissman, 2001). MPP differentiate to produce both sulting junB/Ubi-junB mice progressively develop a
the lymphoid lineage, giving rise to common lymphoid transplantable myeloproliferative disorder (MPD) with
progenitors (CLP) (Kondo et al., 1997), and the myeloid some features of human CML, including eventual pro-
lineage, giving rise to common myeloid progenitors gression to blast crisis associated with an age-depen-
(CMP) (Akashi et al., 1999). CMP, in turn, differentiate dent and what was originally described to be myeloid-
into megakaryocytic/erythroid progenitors (MEP) and specific silencing of the Ubi-junB transgene (Passegue´
myelomonocytic progenitors (GMP), which finally pro- et al., 2001). Remarkably, inactivation of junB expression
is also observed in some human CML patients (Bru-
chova et al., 2002; Yang et al., 2003), and downregulation*Correspondence: passegue@stanford.edu
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of junB expression is consistently found in AML patients and all lineages of mature cells were dramatically re-
duced in number. Together, these results indicate thatexpressing high levels of HoxA9 (Dorsam et al., 2003).
Together, these findings suggest that junB inactivation raising JunB levels in LT-HSC decreases the frequency
of stem cells.could be important for MPD development and perhaps
overt myeloid leukemia including CML.
Here, we use the junB/Ubi-junB model, as well as Increased Frequency of LT-HSC and GMP
several novel models of conditional inactivation and in junB/Ubi-junB Mice
overexpression of junB in hematopoietic cells, to investi- To determine the stages of hematopoietic development
gate the function of JunB during normal and leukemic that are affected in the junB/Ubi-junB model of MPD,
hematopoiesis. We find that loss of junB expression we next examined the frequency and fate of stem cell and
leads to MPD development only when occurring at the myeloid progenitor populations using 6- to 9-month-old
stem cell level and that the LT-HSC is the sole develop- junB/Ubi-junB mice (Figure 2). The junB/Ubi-junB
mental stage containing the LSC for the junB-deficient mice develop by 3 to 6 months of age an MPD character-
MPD. Moreover, we identify JunB as a key negative ized by a massive granulocytic expansion in the bone
regulator of LT-HSC function, controlling the numbers marrow and spleen (Figures 2A and 2B), eventually fol-
of LT-HSC by regulating several cellular mechanisms lowed by the appearance of undifferentiated blast cells
that are critical for maintenance of the stem cell com- leading to a myeloid blast crisis in 16% of the mice
partment, i.e., proliferation/senescence and apoptosis, (Passegue´ et al., 2001). Initial analysis of junB/Ubi-
via changes in the expression levels of crucial effector junB bone marrow revealed a considerable increase in
genes, including the cell cycle regulators p16INK4a and HSC-enriched (Lin/c-Kit/Sca-1) and myeloid pro-
the antiapoptotic proteins Bcl2 and Bclxl. genitor-enriched (Lin/c-Kit/Sca-1) populations (Fig-
ure 2A). Further investigation indicated that the increase
in multipotent bone marrow cells resulted exclusivelyResults
from an increase in the numbers of LT-HSC (Lin/c-Kit/
Sca-1/Flk-2), while the numbers of ST-HSC and MPPEnforced Expression of JunB in LT-HSC Causes
remained similar to those found in control mice. In theStem Cell Loss
myeloid lineage, only the GMP population (Lin/c-Kit/To test the role for JunB during normal hematopoiesis,
Sca-1/CD34/FcR) displayed a massive expansion,we analyzed the consequences of enforced expression
which accounted almost entirely for the increased num-of JunB in stem cells (Figure 1). Highly purified popula-
bers of myeloid progenitors found in junB/Ubi-junBtions of LT-HSC (Lin/c-Kit/Sca-1/Thy1.1int) (Morrison
mice, while the numbers of CMP and MEP remainedet al., 1997) were isolated from C57BL/6-Ly5.2 mice,
very similar to control animals (Figure 1A). Abnormallytransduced with junB-containing [junB(L)] or control
high numbers of cells with the phenotypic characteris-[Co(L)] lentiviruses, and transplanted into lethally irradi-
tics of LT-HSC and GMP were also observed in theated C57BL/6-Ly5.1 congenic recipients (Figure 1A).
enlarged spleens of junB/Ubi-junB mice (Figure 2B).Both lentiviruses infected LT-HSC with similar efficiency
(37% to 45% transduction efficiency), and FACS analy-
sis of peripheral blood isolated from recipient mice at Stochastic Inactivation of JunB
in junB/Ubi-junB LT-HSC3 weeks post-transplantation revealed similar engraftment
and short-term multilineage reconstitution (Figure 1B; To correlate the specific expansion of the LT-HSC and
GMP populations with junB expression, we investigateddata not shown). However, over time, a dramatic decline
in the numbers of transduced Ly5.2/GFP cells was by qRT-PCR the expression profile of the Ubi-junB trans-
gene within the hematopoietic system of both Ubi-junBobserved in the blood of mice transplanted with junB(L)-
transduced HSC compared to the fairly constant level transgenic mice and junB/Ubi-junB MPD mice (Figure
2C). QRT-PCR revealed high expression levels of thefound in the blood of mice transplanted with Co(L)-trans-
duced HSC. At 9 weeks post-transplantation, we used Ubi-junB transgene among the pool of multipotent bone
marrow cells (LT-HSC, ST-HSC, and MPP) isolated fromquantitative real-time RT-PCR (qRT-PCR) analysis of
HSC-derived Ly5.2/GFP spleen cells to assay the in- Ubi-junB transgenic mice, with considerably lower levels
in the myeloid progenitor populations (CMP, GMP, andcrease in junB levels provided by the lentiviral transduc-
tion (Figure 1C). At 20 weeks post-transplantation, we MEP) and B cells, and no expression in mature granulo-
cytes. Strikingly, a similar analysis performed on popula-determined the distribution of transduced Ly5.2/GFP
cells in the stem, progenitor, and mature compartments tions isolated from 6- to 9-month-old junB/Ubi-junB
mice showed dramatically reduced expression levels ofof recipient mice (Figures 1D–1F). Although transduction
with the junB(L) lentivirus resulted in a modest 1.8-fold the Ubi-junB transgene in every cell type, including LT-
HSC, and, consequently, a major reduction in total junBincrease in total junB mRNA levels, dramatically reduced
numbers of HSC-derived Ly5.2/GFP cells were found mRNA levels in the entire hematopoietic system of the
junB/Ubi-junB mice (Figure 2C). Inactivation of thein the bone marrow, spleen, and thymus of the trans-
planted mice. Furthermore, in the bone marrow, almost Ubi-junB transgene in the myeloid lineage of junB/Ubi-
junB mice has been described previously (Passegue´ etno junB(L)-transduced Ly5.2/GFP cells with the phe-
notypic characteristics of LT-HSC (Lin/c-Kit/Sca-1/ al., 2001). However, these results indicate that transgene
inactivation occurs already in the stem cell compart-Flk2) (Christensen and Weissman, 2001), myeloid pro-
genitors (Lin/c-Kit/Sca-1/CD34/FcR) (Akashi et al., ment, consistent with the hypothesis that clones of LT-
HSC that inactivate junB expression have a competitive1999), or lymphoid progenitors (Lin/Il-7R/Thy1.1/
c-Kitint/Sca-1int) (Kondo et al., 1997) could be detected, advantage over LT-HSC that still express the Ubi-junB
JunB Regulates HSC Numbers
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Figure 1. Enforced Expression of junB in LT-HSC Causes Stem Cell Loss
(A) Schematic representation of the lentiviral transduction/transplantation protocol. LT-HSC were purified from C57BL/6-Ly5.2 mice, infected
overnight with an empty control [Co(L)] or a junB-expressing [junB(L)] lentivirus and transplanted into lethally irradiated C57BL/6-Ly5.1 congenic
recipient mice (2,000 transduced-HSC/mouse). hPGK: human PGK promoter; MCS: multiple cloning site; ires: internal ribosomal entry site;
eGFP: enhanced green fluorescent protein.
(B) Peripheral blood chimerism in mice transplanted with junB(L)- or Co(L)-transduced HSC. Data are plotted as percent (mean  SD; n  5)
of GFP cells in peripheral blood mononuclear cells (PBMC).
(C) QRT-PCR analysis of junB mRNA levels in transduced HSC-derived (Ly5.2/GFP) spleenocytes at 9 weeks post-transplantation. Results
have been standardized for -actin levels and are expressed as fold-induction (mean  SD; n  3) compared to the levels detected in Co(L)-
transduced cells (set to 1).
(D–F) Flow cytometric analysis of Co(L)- and junB(L)-transduced HSC-derived (Ly5.2/GFP) cells at 20 weeks post-transplantation. (D) Overall
percentage in the bone marrow. (E) Distribution in the multipotent cell (MC: Lin/c-Kit/Sca-1), myeloid progenitor (MP: Lin/c-Kit/Sca-1/
CD34/FcR), and lymphoid progenitor (CLP: Lin/IL7R/Thy1.1/c-Kit/Sca-1) populations. (F) Distribution in the indicated hematopoietic
lineages in the bone marrow (BM), spleen (Sp), and thymus (Thy). Bar graphs indicate the total cell number (mean  SD; n  3) per four long
bones or per spleen for each of the indicated populations. Gr: Gr-1/Mac-1; B: B220/CD19; T: CD4. Mice transplanted with junB(L)-
transduced HSC displayed on average 20%–50% decrease in total cellularity in both bone marrow and spleen compared to mice transplanted
with Co(L)-transduced HSC (not shown).
transgene, such that junB-deficient LT-HSC and their ment, we crossed mice carrying a floxed allele of junB
(junBf) (Kenner et al., 2004) with a granulocyte lineage-progeny progressively take over hematopoiesis in
junB/Ubi-junB mice. specific MRP8-Cre-ires/GFP transgenic mouse (Figure
3). The human MRP8 promoter restricts CRE recombi-
nase activity, as well as expression of the GFP marker,Targeted Inactivation of JunB during Myelopoiesis
Does Not Cause MPD to granulocytes and a fraction of GMP (10%–20%) (Fig-
ures 3A and 3B) (Lagasse and Weissman, 1994). Consis-To identify directly the developmental stage where inac-
tivation of junB expression is required for MPD develop- tent with this expression pattern, specific deletion of the
Cell
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Figure 2. Specific Expansion of the LT-HSC and GMP Populations in junB-Deficient junB/Ubi-junB MPD Mice
Analysis of 6- to 9-month-old control (junB/ or junB/ with or without the Ubi-junB transgene) and junB/Ubi-junB mice.
(A and B) Detailed FACS analysis of the granulocytic (Gr: Gr-1/Mac-1), multipotent cell (MC: Lin/c-Kit/Sca-1), stem cell (HSC: Lin-/c-Kit/
Sca-1/Flk-2), and myeloid progenitor (MP: Lin/c-Kit/Sca-1/CD34/FcR) populations in the bone marrow (BM) and spleen (Sp). Bar graphs
indicate the total cell number (mean  SD; n  3) per four long bones or per spleen for each of the indicated populations. By 6 months of
age, the junB/Ubi-junB mice display on average a 1.4-fold increase in total cellularity in the bone marrow and a 2.7-fold increase in the
spleen compared to control mice (not shown).
(C) QRT-PCR analysis of Ubi-junB transgene (upper panel) and total junB (bottom panel) mRNA levels in wild-type (wt; n  3), Ubi-junB
transgenic (n 2), and junB/Ubi-junB (n 3) bone marrow. Results are given as mean (SD) of independently sorted sets of stem, progenitor,
and mature cell populations. Each value has been standardized for -actin expression level and is expressed as fold induction compared to
Ubi-junB levels in unfractionated transgenic bone marrow (set to 1; top panel) or to junB levels in unfractionated wild-type bone marrow (set
to 1; bottom panel). B: B220/CD19 spleenocytes; n.d.: not detected.
JunB Regulates HSC Numbers
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Figure 3. Myeloid-Restricted Deletion of junB Does Not Lead to MPD
(A and B) Characterization of MRP8-Cre-ires/GFP transgenic mice. (A) FACS analysis of GFP expression in myeloid progenitor (MP: Lin/
c-Kit/Sca-1/CD34/FcR) and granulocytic (Gr: Gr-1/Mac-1) populations in the bone marrow (BM). (B) QRT-PCR analysis of Cre and Gfp
mRNA levels. Results (mean  SD; n  3) have been standardized for -actin expression levels and are expressed as a percentage of the
maximal expression levels detected in granulocytes (set to 100%). HSC: Lin/c-Kit/Sca-1 bone marrow cells; B: B220/CD19 spleenocytes;
T: CD4 spleenocytes.
(C–E) Analysis of junBf/fMRP8-Cre-ires/GFP (junB(/)Gr) mice. (C) PCR analysis (upper panel) of wild-type (wt or junB) and floxed junB (junBf)
alleles in genomic DNA extracted from each of the indicated populations. Genomic DNA from spleenocytes (Sp) of the indicated genotypes
were used as control. Real-time PCR quantification (lower panel) of the efficiency of deletion of the floxed junB alleles in the same genomic
DNA. Results have been standardized for -actin DNA levels and are expressed as percentages of the levels detected in HSC (set to 100%).
(D) QRT-PCR analysis of junB mRNA levels in the myeloid lineage of wild-type and junB(/)Gr mice. Results (mean  SD; n  3) have been
standardized for -actin levels and are expressed as percentages of the levels detected in control CMP (set to 100%). (E) Detailed FACS
analysis of the myeloid progenitor (MP) and granulocytic (Gr) populations in junB(/)Gr bone marrow. Bar graphs indicate the total cell number
(mean  SD; n  3) per four long bones or per spleen for each of the indicated populations.
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floxed junB allele was observed in a subset of the GMP highly purified subpopulations isolated from 6- to
9-month-old junB/Ubi-junB mice in sublethally irradi-and in most, if not all, granulocytes of the junBf/fMRP8-
Cre-ires/GFP (junB(/)Gr) mice (Figure 3C), correlating ated immunocompromised RAG2-deficient congenic
recipient mice (Table 1; Supplemental Figure S2 online).with reduced levels of junB mRNA in GMP and no detect-
able expression in granulocytes (Figure 3D). Increased While unfractionated bone marrow always transferred
the MPD in secondary recipient mice, c-Kit-depletednumbers of GMP and granulocytes were observed in the
bone marrow of junB(/)Gr mice, but no significant expan- bone marrow did not, suggesting that the LSC resides
in the stem or myeloid progenitor pools. However, nei-sion of the granulocytic population was observed in the
spleen (Figure 3E). Furthermore, none of the junB(/)Gr ther the CMP nor the GMP populations transplanted the
MPD or persisted in the primary recipient mice for longermice (n  18) analyzed over an observation period of
12 months showed evolution of this indolent expansion than 6 weeks, similar to transplantation of wild-type
progenitor populations (Akashi et al., 1999; Na Nakornof the granulocytic lineage to blast crisis, MPD, or overt
leukemia. Therefore, targeted inactivation of junB in non- et al., 2002). Furthermore, CMP and GMP isolated from
junB/Ubi-junB mice displayed normal clonogenic pro-self-renewing myeloid progenitors is not sufficient for
MPD development. genitor activity in vitro, with 80%–90% of the cells plated
giving rise to colonies. Transplantation of high numbers
of (Lin/c-Kit/Sca-1) bone marrow cells containing aTargeted Inactivation of JunB in LT-HSC
mixture of CMP, GMP, and MEP also failed to repopulateResults in MPD
or transplant the MPD to recipient mice (Table 1),We next crossed the floxed junB mice with two different
thereby excluding the possibility of a higher cell numbertransgenic mice that can induce CRE expression in stem
requirement. Within the pool of multipotent bone marrowcells (Figure 4): the constitutive MORE-Cre knockin mice
cells, only transplantation of LT-HSC resulted in the(Tallquist and Soriano, 2000) and the inducible Mx-Cre
propagation of the MPD, while transplantation of themice (Ku¨hn et al., 1995). The MORE-Cre allele restricts
immediate next developmental stages, ST-HSC andthe CRE recombinase activity to the embryo proper,
MPP, did not (Table 1). Strikingly, as few as 60 LT-thereby allowing the birth of junBf/fMORE-Cre (junB/)
HSC were sufficient to transfer the disease to secondarymice (Figure 4A), which develop several pathologies,
recipients (data not shown). The MPD that developedincluding a severe osteoporosis by 4 weeks of age (Ken-
in the LT-HSC-transplanted recipient mice closely mim-ner et al., 2004) and, by 3 to 6 months, an MPD with
icked the disease occurring in primary donor mice, withmassive granulocytic expansion in bone marrow and
increased LT-HSC and GMP populations and eventualspleen (Figure 4D; Supplemental Figure S1A at http://
emergence of undifferentiated blast cells (Supplementalwww.cell.com/cgi/content/full/119/3/431/DC1/).
Figure S3 online). Transplantation of junB/Ubi-junBThree-month-old junB/ mice showed undetectable
spleen cells, which contain high numbers of cells withlevels of the floxed junB allele in LT-HSC, correlating
the phenotypic characteristics of LT-HSC, also trans-with a complete absence of junB mRNA expression (Fig-
planted the MPD in primary recipient mice (Table 1).ures 4B and 4C), and, similarly to the junB/Ubi-junB
Similar results were obtained using lethally irradiatedmice, displayed a massive and specific expansion of
nonimmunocompromised congenic recipient mice, al-the LT-HSC and GMP populations (Figure 4D). To further
though this model resulted in longer intervals for MPDstudy the correlation between stem cell deletion of junB
development following transplantation of unfraction-and MPD development in adult mice, we also used in-
ated bone marrow or purified LT-HSC (data not shown),ducible Mx-Cre transgenic mice that, upon injection of
possibly implicating a role for immunosurveillance inthe interferon  inducer poly(I/C), induces CRE recombi-
this disease. Finally, transplantation experiments werenase activity in numerous cell types including stem cells
also performed with highly purified LT-HSC and a mix-in junBf/f Mx-cre [junB(/)i] mice (Figure 4E). Two months
ture of CMP, GMP, and MEP (Lin/c-Kit/Sca-1) iso-after poly(I/C) injection, we confirmed complete deletion
lated from 3-month-old junB/ mice or from junB(/)iof the floxed junB allele in LT-HSC (Figure 4F) and com-
mice 4 months after poly(I/C) injection (Table 1). Similarlyplete loss of junB mRNA expression in LT-HSC (Figure
to the junB/Ubi-junB mice, using these two genetically4G). Following sustained inactivation of junB, all junB(/)i
defined mouse models, we found that only transplanta-mice displayed a progressive and specific expansion of
tion of unfractionated bone marrow or purified LT-HSCthe LT-HSC and GMP populations, which led by 6-9
was capable of propagating the MPD to recipient mice.months post-poly(I/C) injection to the development of
Together, these results clearly demonstrate that the LSCan MPD with massive granulocytic expansion in bone
are contained within the LT-HSC population, therebymarrow and spleen (Figure 4H; Supplemental Figures
establishing that the junB-deficient MPD is a hematopoi-S1B and S1C on the Cell website). Together, these re-
etic stem cell leukemia.sults indicate that inactivation of junB in hematopoietic
stem cells is absolutely required for MPD development.
They also suggest that junB-deficient HSC and GMP are JunB Regulates LT-HSC Numbers through
qualitatively different in their ability to promote leukemo- Changes in Proliferation and Apoptosis
genesis. Finally, we analyzed junB-deficient LT-HSC and junB(L)-
expressing LT-HSC to identify cellular and molecular
mechanisms that are affected by the loss or gain of junBThe junB-Deficient MPD
Is an HSC Leukemic Disorder expression and are critical for maintenance of the stem
cell compartment (Figure 5). Cell cycle analysis usingTo identify the developmental stage that contains the
LSC for the junB-deficient MPD, we first transplanted Hoechst-33342 showed similar percentages of G0-G1
JunB Regulates HSC Numbers
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Figure 4. Stem Cell Deletion of junB Leads to MPD
(A) Schematic representation of the MORE-Cre-mediated deletion of the floxed junB alleles during embryonic development. The MORE
promoter restricts CRE expression to the embryo proper and allows the birth of junBf/fMORE-Cre (junB/) mice, which are junB deficient in
every cell type.
(B–D) Analysis of 3-month-old junB/ mice. (B) PCR analysis of wild-type (wt) and floxed junB (junBf) alleles in genomic DNA extracted from
bone marrow (BM) or LT-HSC purified from mice of the indicated genotype. (C) QRT-PCR analysis junB mRNA expression in bone marrow
and LT-HSC purified from wild-type and junB/ mice. Results (mean  SD; n  3) have been standardized for -actin levels and are expressed
as percentages of the levels detected in wild-type bone marrow (set to 100%). (D) Detailed FACS analysis of the granulocytic (Gr: Gr-1/Mac-
1), multipotent cell (MC: Lin/c-Kit/Sca-1), stem cell (HSC: Lin/c-Kit/Sca-1/Flk-2), and myeloid progenitor (MP: Lin/c-Kit/Sca-1/CD34/
FcR) populations in junB/ bone marrow. Bar graphs indicate the total cell number (mean  SD; n  3) per four long bones or per spleen
(Sp) for each of the indicated populations. JunB/ mice display on average a 1.6-fold increase in total cellularity in the bone marrow and a
1.3-fold increase in the spleen compared to wild-type mice (not shown).
(E) Schematic representation of the Mx-Cre-mediated deletion of the floxed junB alleles following poly(I/C) injection in junBf/fMx-Cre
(junB(/)i) mice.
(F–H) Analysis of junB(/)i mice. (F) PCR analysis of floxed junB allele in genomic DNA extracted from bone marrow or LT-HSC purified from
mice of the indicated genotypes at 2 months post-poly(I/C) injection. (G) QRT-PCR analysis of junB mRNA expression in bone marrow and
LT-HSC purified from junBf/f and junB(/)i mice at 2 months post-poly(I/C) injection. Results (mean  SD; n  3) have been standardized for
-actin levels and are expressed as percentages of the levels detected in junBf/f bone marrow (set to 100%). (H) Detailed FACS analysis of
the multipotent cell (MC), myeloid progenitor (MP), and granulocytic (Gr) populations in junB(/)i bone marrow at the indicated time post-
poly(I/C) injection. Bar graphs indicate the total cell number (mean  SD; n  3) per four long bones or per spleen for each of the indicated
populations in control junBf/f and poly(I/C)-injected junB(/)i mice.
and S-G2/M cells in control LT-HSC populations and LT-HSC compared to control LT-HSC (Figure 5B). How-
ever, junB-deficient and control LT-HSC gave rise withjunB-deficient LT-HSC populations isolated from 6- to
9-month-old junB/Ubi-junB mice (Figure 5A). Since similar efficiency to the entire range of myeloid and
erythroid colonies in methylcellulose CFU assays (Figurethe absolute numbers of LT-HSC are increased in these
MPD mice, this result indicates an increase in both rest- 5C), indicating that both LT-HSC populations are equiva-
lent in their differentiation capabilities in vitro and in vivo.ing and cycling LT-HSC numbers. Consistently, prolifer-
ation analyses of single LT-HSC cultured in Terasaki Interestingly, junB-deficient LT-HSC showed decreased
mRNA levels of the cell cycle inhibitor p16Ink4a, a directplates indicated faster proliferation rates and increased
cell numbers generated from a single junB/Ubi-junB junB-target gene (Passegue´ and Wagner, 2000) and a
Cell
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Table 1. The Transplantable Leukemic Stem Cells for the junB-Deficient MPD Reside in the LT-HSC Compartment
Number Number Number Observation
of Donors of Cells of Recipients Time (Months) MPD Blast Crisis
junB/Ubi-junB
Bone marrow 5 2 	 106 16 2–12 16/16 2/16
c-Kit-depleted BM 4 5 	 106 5 up to 12 0/5
LT-HSC 4 2,000 9 2–5 9/9 1/9
ST-HSC & MPP 4 3,000 10 up to 12 0/10
CMP 3 5,000 7 up to 5 0/7
GMP 3 10,000 8 up to 5 0/8
CMP, GMP, and MEP 2 5 	 105 4 up to 12 0/4
Spleen 2 5 	 106 6 up to 12 5/6
junBf/fMORE-Cre (junB/)
Bone marrow 3 2 	 106 5 6–12 5/5 0/5
LT-HSC 3 2,000 8 5–12 8/8 1/8
CMP, GMP, and MEP 3 5 	 105 5 up to 12 0/5
junBf/fMx-Cre (junB(/)i)
Bone marrow 2 2 	 106 6 6–12 6/6 0/6
LT-HSC 2 2,000 6 8–12 6/6 0/6
CMP, GMP, and MEP 2 5 	 105 4 up to 12 0/4
Sublethally irradiated RAG2/-Ly5.2 recipient mice were injected with the indicated numbers of donor bone marrow cells, spleen cells, or
purified stem and/or progenitor populations isolated from 6- to 9-month-old junB/Ubi-junB-Ly5.1 mice, 3-month-old junBf/fMORE-Cre
(junB/)-Ly5.1 mice, or junBf/fMx-Cre (junB(/)i)-Ly5.1 mice 4 months after poly(I/C) injection. Recipient mice were monitored monthly by flow
cytometric analysis of peripheral blood and scored positive for MPD when neutrophil counts were above 50%. Spleen and bone marrow cells
from the diseased recipient mice were further analyzed by flow cytometry and histology to confirm the MPD diagnosis and to determine the
occurrence of blast crisis.
key regulator of stem cell proliferation/senescence (Park leading to MPD development. MPD was observed in
every mouse model in which we could establish condi-et al., 2003), and increased expression of the antiapo-
ptotic proteins bcl2 and bclx(L), two critical regulators tions for LT-HSC deletion of junB, either in a stochastic
manner (junB/Ubi-junB model) or in a direct mannerof stem cell death (Domen, 2000) (Figures 5D and 5E).
Conversely, cell cycle analysis of Ly5.2/GFP-trans- (junBf/fMore-Cre and junBf/fMx-Cre models). Both junB
deletion and junB overexpression deregulate cellularduced junB(L)-expressing LT-HSC, isolated from recipi-
ent mice 9 weeks after transplantation, revealed a signif- mechanisms, such as proliferation/senescence and
apoptosis, that are critical for maintenance of the stemicant decrease in the numbers of cycling cells compared
to Co(L)-expressing LT-HSC (Figure 5F); and prolifera- cell compartment. JunB effects are mediated, at least
in part, via regulation of the expression of key effectorstion analysis of single Ly5.2/GFP-transduced junB(L)-
expressing LT-HSC in Terasaki plates also indicated a genes, like p16Ink4a, bcl2, and bclx(L), which also have been
shown to be important in mediating JunB effects duringreduction in the numbers of cells generated from a single
stem cell (Figure 5G). Most importantly, analysis by qRT- myelopoiesis (Passegue´ et al., 2001). Recently, Bmi-1,
a negative regulator of p16Ink4a, has been shown to bePCR indicated a massive increase in the levels of p16Ink4a
expressed in Ly5.2/GFP junB(L)-transduced HSC- critical for the self-renewal capability of normal hemato-
poietic stem cells (Park et al., 2003) and myeloid leuke-derived cells as well as some decrease in the levels of
bcl2 and bclx(L) expressed (Figure 5H). Taken together, mia cells (Lessard and Sauvageau, 2003), as well as of
central nervous system (CNS) and peripheral nervousthese findings underscore the key biological function of
JunB in regulating homeostasis of the stem cell com- system (PNS) stem cells (Molofsky et al., 2003). Deregu-
lation of other molecular pathways perhaps involved inpartment (Figure 6). The expanded population of LT-
HSC found in junB-deficient MPD mice could arise from controlling stem cell self-renewal (Reya et al., 2001),
inhibition of programmed cell death (Traver et al., 1998),deregulated self-renewing replication, which occurs
without impaired differentiation, and/or could be medi- or conservation of telomeres (Allsopp and Weissman,
2002) are also likely to contribute to the leukemic fateated through blockade of apoptosis and/or senescence,
while the stem cell loss caused by increased JunB levels of the junB-deficient LT-HSC and are currently being in-
vestigated.could be due to decreased proliferation, increased se-
nescence, and/or increased apoptosis. Although targeted inactivation of JunB in stem cells
leads to a massive expansion of the LT-HSC population,
normal numbers of ST-HSC, MPP, CLP, and CMP wereDiscussion
derived from junB-deficient LT-HSC, indicating that
JunB does not control the population size of these pro-In the present study, we demonstrate that the transcrip-
tion factor JunB plays a key biological role in control- genitor compartments. Other genes and/or environmen-
tal influences, which are still unknown, are thereforeling homeostasis of the hematopoietic stem cell com-
partment (Figure 6). We found that raising JunB levels likely to independently regulate the numbers of these
hematopoietic subsets. In contrast, JunB expression isin LT-HSC through lentiviral transduction leads to stem
cell loss, while inactivating JunB expression in LT-HSC critical for homeostasis of the granulocytic lineage since
junB-deficient LT-HSC produce vastly increased num-inevitably causes a leukemogenic stem cell expansion
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Figure 5. JunB Alters the Homeostasis of the Stem Cell Compartment due to Changes in Proliferation and Apoptosis
(A–E) Analysis of LT-HSC purified from 6- to 9-month-old control (junB/ or junB/ with or without the Ubi-junB transgene) and junB/Ubi-
junB mice. (A) Hoechst-33342 staining for DNA content. The percent of cells in S-G2/M phase of the cell cycle (with 
2N DNA content) is
indicated. (B) Analysis of the proliferation rate of single LT-HSC. Data are plotted as the total number (mean  SD) of cells per Terasaki well
over a 5 day period in culture. (C) Methylcellulose colony-forming units (CFU) assays. Colony types include mix (Mix), granulocyte/macrophage
(GM), granulocyte (G), macrophage (M), erythroid (E), megakaryocyte (Mk), and erythroid/megakaryocyte (EMk). Granulocyte-containing colonies
derived from junB/Ubi-junB LT-HSC are always larger in size than colonies derived from control LT-HSC (not shown). (D) QRT-PCR analysis
of p16Ink4a, bcl2, and bclx(L) mRNA levels. Results (mean SD; n 3) have been standardized for -actin levels and are expressed as percentages
of the levels detected in wild-type (wt) LT-HSC (set at 100%). (E) Intracellular staining for mouse Bcl2. Data are plotted as histograms of
fluorescence intensity.
(F–G) Analysis of (Ly5.2/GFP) LT-HSC purified from mice transplanted with Co(L)- or junB(L)-transduced HSC at 9 months post-transplanta-
tion. (F) Hoechst-33342 staining for DNA content. (G) Analysis of the proliferation rate of single LT-HSC.
(H) QRT-PCR analysis of p16Ink4a, bcl2, and bclx(L) mRNA levels in (Ly5.2/GFP) spleen cells purified from mice transplanted with Co(L)- or
junB(L)-transduced HSC at 9 months post-transplantation. Results (mean  SD; n  3) have been standardized for -actin levels and are
expressed as percentages of the levels detected in Co(L)-transduced cells (set at 100%).
bers of GMP and of mature granulocytes as already stasis of the granulocytic lineage and never leads to
MPD development, clearly indicating that the target cellreported (Passegue´ et al., 2001). Interestingly, enforced
expression of JunB in LT-HSC leads to a dramatic de- for JunB inactivation is critical for the leukemogenic
process. In fact, transplantation experiments indicatecline in the numbers of mature cells belonging to all the
hematopoietic lineages, while junB inactivation leads that LT-HSC, but not GMP or other multipotent or oligo-
potent progenitor population, are the only cell popula-to a specific increase in LT-HSC and GMP/granulocyte
populations. Since junB-overexpressing HSC are lost, tion capable of propagating the junB-deficient MPD in
recipient mice. Taken together, these results demon-the effects on mature populations may be secondary
to that loss, although we cannot yet exclude a more strate that the LT-HSC population contains the LSC for
the junB-deficient MPD and identify this disease as apromiscuous effect of junB overexpression that could
involve additional regulatory pathways distinct from the hematopoietic stem cell leukemia.
Perhaps the most common MPD in man is the chronicones affected in junB-deficient LT-HSC. Most impor-
tantly, targeted inactivation of junB in mouse-committed phase of CML (Sawyers, 1999). Acquisition of the t(9;22)
Bcr-Abl translocation is an early and almost constantmyelomonocytic cells only modestly affects the homeo-
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Figure 6. Proposed Model for the Role of
JunB during Normal and Leukemic Hemato-
poiesis
During normal hematopoiesis, JunB regu-
lates the homeostasis of the stem cell com-
partment by controlling the balance between
self-renewal replication and apoptosis. In
junB-deficient mice, the absence of JunB
leads to increased numbers of LT-HSC, due,
at least in part, to increased proliferation and/
or blockade of apoptosis, while the numbers
of differentiating ST-HSC, MPP, CLP, and
CMP remain normal. JunB also controls the
homeostasis of the granulocytic lineage lead-
ing to a vast expansion of GMP and mature
granulocytes in mice harboring stem cell in-
activation of junB. The expanded population
of LT-HSC is the LSC of the junB-deficient
MPD, e.g., the only population capable of
transplanting the disease to recipient mice,
while the expanded GMP and granulocyte
populations provide the myeloproliferative
features of this stem cell leukemia.
event in human chronic phase CML. The activity of the hypermethylation (Yang et al., 2003). JunB is also regu-
lated by the homeoprotein HoxA9 and consistent down-Bcr-Abl fusion protein is central in the development of
CML, but it is now clear that other transformation events regulation of junB expression is observed in AML pa-
tients with high HoxA9 expression (Dorsam et al., 2003).are also required for its leukemic progression. The Bcr-
Abl translocation can be found in normal human hemato- Together, these findings suggest that junB inactivation
could be a general mechanism involved in myeloid leu-poietic cells in the absence of leukemic transformation
(Bose et al., 1998; Matioli, 2002), suggesting the exis- kemias and a contributing factor for some of the human
CML pathologies that show granulocytocis and myeloidtence and likely importance of additional mutations and/
or epigenetic changes that could be required alone or blast crisis.
Here, we clearly demonstrate that junB inactivationin conjunction with Bcr-Abl for CML pathogenesis (Fial-
kow et al., 1981; Clarkson et al., 2003; Feldman et al., 2003). must occur in LT-HSC, and not at later stages of myelo-
poiesis, to induce MPD development. In contrast, re-Transgenic mice overexpressing the Bcr-Abl oncogene in
hematopoietic lineages also have requirements for leuke- stricted expression of Bcr-Abl in mouse-committed my-
elomonocytic cells can lead to CML development withoutmic evolution. In fact, Bcl2-mediated inhibition of apoptosis
in mice (Jaiswal et al., 2003) and recently -catenin-driven stem cell involvement (Jaiswal et al., 2003). Although
the hMRP8-Bcr-Abl model may not recreate the fullself-renewal in humans (Jamieson et al., 2004), have
been implicated as synergistic events for CML progres- spectrum of human CML diseases, particularly the
lymphoid crisis component, it suggests that expressionsion to its final blast crisis stage. Remarkably, junB ex-
pression is inactivated in peripheral blood cells of Bcr- of Bcr-Abl may be required only at the committed myelo-
monocytic stage to cause the disease, although theAbl-positive CML patients (Bruchova et al., 2002; Yang
et al., 2003), mainly due to, or sustained by, hypermethy- translocation would have to be present (through not
necessarily expressed) in LT-HSC, as these are the onlylation silencing of the junB promoter (Yang et al., 2003).
Furthermore, the demethylating agent Decitabine, which self-renewing cells in the hematopoietic system. To-
gether, these results suggest a progression in the CMLshows encouraging anti-CML activity and promising re-
sults for the treatment of Imatinib Mesylate-resistant leukemogenesis process that could eventually apply to
some human pathologies. Hence, stem cell inactivation(Gleevec, formally STI571) patients (Kantarjian et al.,
2003), leads to partial reactivation of human junB ex- of junB could precede or follow acquisition of Bcr-Abl
expression by the stem cells, or by more committedpression that had previously been silenced by promoter
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number of granulocyte in the bone marrow and no extramedullarmyeloid progenitor populations, and cooperate with
hematopoiesis. Myeloproliferative disease (MPD) corresponds to anBcr-Abl for the genesis and/or progression of chronic
increase by 
2-fold in the total number of granulocytes in the bonephase CML. This role for junB is currently under investi-
marrow and to an increase in the relative frequency of granulocytes
gation and the junB-deficient MPD mice may prove to be by 
20% in the spleen and by 
50% in the blood, extramedullar
valuable mouse models to study Bcr-Abl-independent hematopoiesis, and transplantability of the disease. Overt myeloid
leukemia corresponds to all the previous plus anemia and 
20%mechanisms that may function alone or in cooperation
blast cells.with Bcr-Abl in the genesis and/or progression of CML.
Studying the relationship between Bcr-Abl signaling and
Flow CytometryjunB regulation at both the HSC and the GMP level also
Cell staining and enrichment procedures for cell sorting were per-may provide insight as to why granulocytosis predomi-
formed as described (Kondo et al., 1997; Akashi et al., 1999; Chris-
nates in human CML. tensen and Weissman, 2001). Cells were finally resuspended in
The results presented here provide the first experi- Hanks Buffered Salt Solution (HBSS) with 2% heat-inactivated fetal-
calf serum (staining medium) and 1 g/ml propidium iodide (PI) andmental demonstration of the hematopoietic stem cell
analyzed or sorted on a modified 488 nm argon and 599 nm dye dualleukemia nature of an MPD similar to human chronic
laser FACS Vantage (Becton Dickinson Immunocytometry System).phase CML. They nicely corroborate the less direct evi-
Dead cells were gated out by high PI staining and forward lightdence that the chronic phase of human CML is a clonal
scatter. For proliferation analysis of a single stem cell, one LT-HSC
expansion of multiple hematopoietic lineages and there- was clone-sorted per well of a Terasaki plate in 10 l of Iscove’s
fore derives from HSC or other multipotent cells (Fialkow Modified Dulbecco’s Media (IMDM) containing 5% FCS, 50 mM
2-mercaptoethanol, SCF (20 ng/ml), Flt3L (20 ng/ml), and IL-11 (10et al., 1977; Li et al., 1999). The identification of the LSC
ng/ml) and incubated at 37C for the indicated duration. The num-for the junB-deficient MPD lends further support to the
bers of cells per well were visually determined using an invertednotion that leukemias and cancers may be sustained by
microscope. For Hoechst analysis, c-Kit-enriched bone marrowrare LSC or cancer stem cells (Reya et al., 2001; Pas-
cells were preincubated for 45 min at 37C in staining medium con-
segue´ et al., 2003) that could either derive from the stem taining 1 g/ml glucose, 20 g/ml Hoechst-33342 (Molecular Probes),
cell of the tissue of origin, as shown here, or from more and 50 g/ml Verapamil before the final staining step, also per-
formed in the presence of 50 g/ml Verapamil. Intracellular mBcl2restricted progenitors that have reacquired the stem cell
staining was performed as described (Domen et al., 1998).capability for self-renewal, as we have recently shown
for MLL-ENL-induced mouse AML (Cozzio et al., 2003),
Cell Transplantationin human myeloid blast crisis CML (Jamieson et al.,
Unfractionated bone marrow and spleen cells and purified stem and
2004) and in other human AML (Miyamoto et al., 2000). progenitor populations were obtained from 6- to 9-month-old
Insofar as the only self-renewing cell in the myeloid junB/Ubi-junB-Ly5.1 mice, 3-month-old junBf/fMORE-Cre (junB/)-
lineage is the LT-HSC, we expect that only clones of LT- Ly5.1 mice, or junBf/fMx-Cre (junB(/)I)-Ly5.1 mice 4 months after
poly(I/C) injection and transplanted via retro-orbital injection intoHSC can accumulate all the mutations and/or epigenetic
sublethally irradiated (450 rad) RAG2/-Ly5.2 recipient mice. Pe-changes involved in the progression to leukemia, includ-
ripheral blood was obtained from the tail vein of each mouse anding several independent events to inhibit programmed
analyzed by flow cytometry. Donor-derived cells were distinguished
cell death (Traver et al., 1998), to inhibit differentiation from host cells by the expression of different Ly5 antigens (Ly5.1
(Tenen, 2003) and to enforce self-renewal (Reya et al., versus Ly5.2).
2001; Jamieson et al., 2004). Future investigations of the
junB-deficient LT-HSC should therefore provide a better HSC Lentiviral Transduction and Transplantation
JunB cDNA was cloned upstream of an ires/eGFP sequence intomolecular understanding of LSC pathogenesis and may
a self-inactivating lentiviral vector plasmid and viral stocks werelead to new insights into some features of human MPD
produced by triple transfection of 293T cells along with lentiviralincluding CML.
gag-pol and vesicular stomatitis virus G glycoprotein constructs.
Lentivirus-containing supernatant medium was collected for 2 con-
secutive days and concentrated by ultracentrifugation. HSC wereExperimental Procedures
purified from C57BL/6-Ly5.2 mice and cultured in 200 l in 96-well
plates with concentrated lentiviral stocks (1:50 to 1:100 dilution) inMouse
Iscove’s Modified Dulbecco’s Media (IMDM) containing 5% FCS,The congenic mouse strains C57BL/6-Ly5.1 or Ly5.2 and the
50 M 2-mercaptoethanol, SCF (20 ng/ml), Flt3L (20 ng/ml), and IL-RAG2/-Ly5.2 mice were used as described (Kondo et al., 1997).
11 (10 ng/ml) for 12–16 hr at 37C. Transduced HSC were mixedJunB/Ubi-junB (Schorpp-Kistner et al., 1999), junBf/f (Kenner et
with a radioprotective dose of 2.5 	 105 congenic Sca-1-depletedal., 2004), MORE-Cre (Tallquist and Soriano, 2000), and Mx-Cre
C57BL/6-Ly5.1 helper bone marrow cells and transplanted via retro-(Ku¨hn et al., 1995) mice were generated as described. The MRP8-
orbital injection into lethally irradiated (960 rad) congenic C57BL/Cre-ires/GFP construct was generated by inserting a Cre-ires/GFP
6-Ly5.1 recipients.cassette into the unique BglII site of the human MRP8 expression
vector (Lagasse and Weissman, 1994) and two founder transgenic
Methylcellulose CFU Assayslines were obtained after DNA microinjection into fertilized F1
To support the formation of myeloid colonies, purified LT-HSC (100(C57BL/6 	 C3H) eggs. All the mice were backcrossed between
cells) were cultured in Iscove’s Modified Dulbecco’s Media (IMDM)-two to seven times to the C57BL/6 background before being used
based methylcellulose media (Methocult M3100, StemCell Technol-for the experiments. To induce Mx-Cre-mediated deletion of junB
ogies) supplemented as described (Akashi et al., 1999).during adult hematopoiesis, 4-week-old junBf/fMx-Cre mice were
injected four times at 2-day intervals with 250 g poly(I/C) in 200
l PBS. All mice were maintained in Stanford University’s Research Quantitative RT-PCR Analysis
Total RNA was isolated using Trizol reagent (Invitrogen) from purifiedAnimal Facility in accordance with Stanford University guidelines.
The classification of the nonlymphoid hematopoietic neoplasm de- HSC (2,000 to 5,000 cells), progenitors (10,000 to 30,000 cells), or
mature cell populations (30,000 to 100,000 cells), digested withscribed in this study was performed according to the guidelines
edited by the hematopathology subcommittee of the mouse models DNase I to remove DNA contamination and used for reverse-tran-
scription according to the manufacturer’s instructions (SuperScriptof human cancers consortium (Kogan et al., 2002). Indolent granulo-
cytic expansion corresponds to an increase by 2-fold in the total II kit, Invitrogen). For qRT-PCR analysis, primer sequences were
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designed using Primer Express software (Applied Biosystems) and C., and Lawrence, H.J. (2003). The transcriptome of the leukemo-
genic homeoprotein HOXA9 in human hematopoietic cells. Bloodare available upon request. All reactions were performed in an ABI-
7000 sequence detection system using SYBR Green PCR Core re- 103, 1676–1684.
agents according to the manufacturer’s instructions (Applied Bio- Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A., and
systems). PCR amplification was performed in a 12 l final volume Silver, R.T. (2003). The emergence of Ph-, trisomy-8 cells in patients
containing 1X SYBR Green PCR buffer, 2 mM magnesium chloride, with chronic myeloid leukemia treated with imatinib mesylate. Exp.
0.5 mM dNTP mix with dUTP, 8 ng of each primer, 0.1 U AmpErase Hematol. 31, 702–707.
UNG, 0.25 U AmpliTaq Gold, and 2 l of DNA or cDNA templates
Fialkow, P.J., Jacobson, R.J., and Papayannopoulou, T. (1977).using 50C for 2 min and 95C for 10 min followed by 45 cycles at
Chronic myelocytic leukemia: clonal origin in a stem cell common95C for 15 s and 60C for 1 min. For each sample, expression of
to the granulocyte, erythrocyte, platelet and monocyte/macrophage.the -actin gene was used to normalize the amount of the investi-
Am. J. Med. 63, 125–130.gated transcript.
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